PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the PK, PD and long-term safety of Benralizumab administered
subcutaneously in 30 children aged 6 to 11 years with severe eosinophilic asthma. Up to an
additional 3 Japanese patients aged 12 to 14 years will be enrolled to meet local regulatory
requirements.